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Andraś Kotschy,§ Olivier Geneste, and Roderick E. Hubbard*,,∥
Vernalis (R&D) Ltd., Granta Park, Abington, Cambridge CB21 6GB, U.K.
Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine 78290, France
§Servier Research Institute of Medicinal Chemistry, Budapest 1031, Hungary
∥YSBL, University of York, Heslington, York YO10 5DD, U.K.
*S Supporting Information
ABSTRACT: We describe our work to establish structure- and fragment-based drug discovery to identify small molecules that
inhibit the anti-apoptotic activity of the proteins Mcl-1 and Bcl-2. This identiﬁed hit series of compounds, some of which were
subsequently optimized to clinical candidates in trials for treating various cancers. Many protein constructs were designed to
identify protein with suitable properties for diﬀerent biophysical assays and structural methods. Fragment screening using
ligand-observed NMR experiments identiﬁed several series of compounds for each protein. The series were assessed for their
potential for subsequent optimization using 1H and 15N heteronuclear single-quantum correlation NMR, surface plasmon
resonance, and isothermal titration calorimetry measurements to characterize and validate binding. Crystal structures could not
be determined for the early hits, so NMR methods were developed to provide models of compound binding to guide compound
optimization. For Mcl-1, a benzodioxane/benzoxazine series was optimized to a Kd of 40 μM before a thienopyrimidine hit
series was identiﬁed which subsequently led to the lead series from which the clinical candidate S 64315 (MIK 665) was
identiﬁed. For Bcl-2, the fragment-derived series were diﬃcult to progress, and a compound derived from a published
tetrahydroquinone compound was taken forward as the hit from which the clinical candidate (S 55746) was obtained. For both
the proteins, the work to establish a portfolio of assays gave conﬁdence for identiﬁcation of compounds suitable for
optimization.
1. INTRODUCTION
Mcl-1 and Bcl-2 are members of the family of Bcl-2-like
proteins1 that play a key role in regulating programmed cell
death or apoptosis. The family consists of three classes of
protein which contain between one and four of the so-called
Bcl-2 homology domains (BH1−BH4). The pro-apoptotic
class of protein such as Bax and Bak contains three BH
domains that on activation form pores in mitochondria,
triggering release of caspases leading to cell death. Activation is
by a number of as-yet not fully characterized mechanisms but a
major factor is relief of inhibition by binding to a class of single
BH3-only proteins such as Bim, Puma, Bad, Hrk, and Noxa.
These BH3-only proteins bind variedly to the well-charac-
terized class of anti-apoptotic proteins Mcl-1, Bcl-2, and Bcl-xL
(and less-studied Bcl-w and Bﬂ-1 or A1) which usually have
four BH domains. These anti-apoptotic proteins are frequently
upregulated in cancer cells, sequestering the BH3-only pro-
apoptotic proteins, thus inhibiting apoptosis, and disruption of
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this interaction has been identiﬁed for a long time as a possible
strategy for cancer therapy.
The Bcl-2 family represents a class of proteins for which it is
challenging to generate drug-like molecules2 because of the
generally hydrophobic nature of the large protein−protein
interaction surfaces to be disrupted. A number of other groups
have reported success on these targets.3 For Bcl-2, a series of
clinical candidates eventually led to the marketed drug, ABT-
199,4−6 while a number of other groups report potent Mcl-1
inhibitors7−9 some of which have entered clinical trials. We
have recently disclosed compound series that inhibit Bcl-210
and Mcl-1,11 and members of these series are now in clinical
trials as a therapy for various cancers.
The ﬁrst challenge faced for this class of target is to establish
a robust drug discovery platform, including production of
protein suitable for biophysical and functional assays,
generating structural information and identifying tool com-
pounds which can validate the assays that underpin hit
identiﬁcation and subsequent compound optimization. In this
paper, we describe the development of structure-based
discovery platforms for our Mcl-1 and Bcl-2 projects, which
resulted in identiﬁcation of the hit series of compounds which
were subsequently optimized to clinical candidates. The
structure-guided optimization of a thienopyrimidine series to
cell-active inhibitors of Mcl-1 is described.12 The optimization
of other compounds will be described elsewhere.
Figure 1 shows the structure we determined of the single
helix of Bim bound into the groove provided by Mcl-1, similar
to that of the ﬁrst published structure (pdb code: 2PQK13).
This is architecturally similar to the complexes seen for other
pro-apoptotic/anti-apoptotic pairs such as Bcl-xL with Bad
(pdb code 1g5j) and summarizes the issue for generation of
drug-like, potent inhibitors of the interaction which typically
have subnanomolar aﬃnities.14 Mcl-1 has a large and
predominantly hydrophobic cleft, characterized by a central
charged amino acid (R263), ﬂanked by a series of
predominantly hydrophobic pockets, labeled S1−S5, which
are occupied by the side chains of Bim.
The following sections describe the approach taken to
generate the structure-based discovery platform for both Bcl-2
and Mcl-1 and the fragment and compound screening and
characterization, which led to identifying hit series suitable for
optimization for both the proteins. The description is
organized with separate sections for each of the proteins
under each method and activity. This is because there was
considerable crossover between the projects in the develop-
ment of the methods and identiﬁcation of initial hit
compounds. The experimental methods are described in the
section at the end of the manuscript with additional details
including compound synthesis in the Supporting Information.
2. RESULTS
2.1. Generation of Suitable ProteinBcl-2. Early
structural work on Bcl-xL
15 by a group at Abbott characterized
a long ﬂexible loop between residues 28−80, connecting
helices 2 and 3 in structures determined by both NMR
spectroscopy and X-ray crystallography. This loop can be
truncated with no eﬀect on the function or structure. Bcl-2 has
an equivalent long ﬂexible loop. Work by the same Abbott
group16 found that intact Bcl-2 is not suﬃciently soluble for
structural studies but designed a Bcl-2/Bcl-xL hybrid for two
isoforms of Bcl-2 (hereafter, Bcl-2#1 and Bcl-2#2), where the
loop is shortened with a Bcl-xL sequence. Structures were
reported for these Bcl-2 proteins determined by NMR
spectroscopy.16
We generated Bcl-2#2 but found it was expressed in low
yields and had poor stability in our hands, giving variable
behaviors in NMR experiments. Modiﬁcation of the screening
buﬀers [to 50 mM MES/bis-TRIS pH 7.0, 20 mM Arg/Glu, 2
mM dithiothreitol (DTT)] provided a more stable protein
which was used in initial NMR experiments and for surface
plasmon resonance (SPR). However, we were not able to
obtain crystals of Bcl-2#2 and a more stable protein was
required for more extensive and routine NMR experiments.
Comparison of the sequence of Bcl-2#2 with Bcl-xL and its
crystal structure identiﬁed a number of surface and C-terminal
residues which could have an impact on protein behavior and
crystallization. Modiﬁcations to these residues (shown in
Figure 2) gave a construct we call Bcl-2#3 which was expressed
in high yield. This construct had a similar selectivity proﬁle for
BH3-only peptides as wild-type Bcl-2 and weak interaction
with the Bcl-xL- speciﬁc peptide Hrk (Table S1). Bcl-2#3 was
stable at 800 μM for 2−3 weeks at 30 °C, suitable for structural
studies by both NMR spectroscopy (15N labeled and 15N, 13C
labeled) and X-ray crystallography. In addition, the protein
showed slow exchange on the NMR timescale when binding
potent ligands, with evidence of the increased order (see
Figure S1). A further modiﬁed version was produced (Bcl-
2#3), in which some surface glutamic acids were modiﬁed (to
alanine or glutamine) to remove some carboxylate/carboxylate
interactions seen in crystal packing, and this was used for one
of the crystal structures reported here (2 in Figure 3);
subsequent work on advanced compounds derived from 2
showed the same binding mode in other Bcl-2 constructs.10
Unmodiﬁed human Bcl-2 residues 1−207 with an N-terminal
hexa-His tag and a thrombin cleavage site (hereafter hBcl-2)
was produced for assays.
2.2. Generation of Suitable ProteinMcl-1. The ﬁrst
crystal structures of Mcl-1 were published in 2007 (PDB code:
2NL917) as we began our work on Mcl-1. Mouse Mcl-1
(hereafter mMcl-1) was more soluble than human Mcl-1
(hereafter hMcl-1), and a number of mouse mutations were
introduced into hMcl-1 for this structure. We introduced
further nine mutations to vary surface residues and alter the pI
of the protein and the length of the N and C termini. This
eventually led to the protein we term hMcl-1#1 (with an N-
terminal GST tag and 3C protease cleavage site), which was
used to determine some initial crystal structures with pro-
apoptotic peptides bound (a cartoon representation of the
Figure 1. Crystal structure of the Bim peptide bound to hMcl-1. (a).
Mcl-1 helical structure, colored from N (blue) to C (red) terminus,
with the regions designated BH1−BH4 indicated, and with the Bim
peptide in stick representation. (b). Details of the Bim peptide
binding site on Mcl-1 with labels for the S1−S5 pockets and R263 of
Mcl-1.
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structure of hMcl-1#1 bound to the BH3-only peptide Puma is
shown in Figure S2). We then found that suﬃcient quantities
of soluble hMcl-1 could be generated with no mutations, by
swapping to an N-terminal hexahis tag and either a TEV or
thrombin cleavage site. This hMcl-1 was used for subsequent
crystallographic studies, fragment screening, and various assays
and initial 1H and 15N heteronuclear single-quantum
correlation (HSQC) NMR experiments. In addition, a double
his-tagged version was produced for SPR,18 which was also
suitable for isothermal titration calorimetry (ITC). However,
the lack of long-term solubility of hMcl-1 precluded its use for
routine Kd determination using
1H, 15N HSQC experiments,
and so mMcl-1 was used. Figure 2b compares the sequence in
PDB code 2NL917 with that of mMcl-1, hMcl-1, and hMcl-
1#1.
2.3. Assays To Validate Binding of Compounds to
Proteins. In addition to the 1D 1H NMR methods used in
ligand-observed NMR fragment screening described below,
four diﬀerent assays were developed to validate or characterize
binding of compounds to Bcl-2 or Mcl-1 during this hit
identiﬁcation phase: ﬂuorescence polarisation (FP), 1H, 15N
HSQC NMR, ITC, and SPR. Details of the reagents and
protocols are provided in the Experimental Section, in brief:
2.3.1. FP Assays. Ligand binding was measured from the
change in FP on displacement of the BH3-only peptide, F-
Figure 2. Amino acid sequence of (a) Bcl-2a comparison of the Bcl-2#2 sequence used to generate PDB entry 2o21 and used here for fragment
screening and initial NMR experiments and the sequence designed for the Bcl-2#3 construct, which was used for X-ray crystallography, SPR, and
most NMR experiments. Sequence numbering is for human Bcl-2. Highlighted in green is the loop which is not seen in the crystal structure and
identity between the two sequences is indicated with *; a construct with reduced surface charge (Bcl-2#3) was used for some X-ray crystallography
with E to A mutations at positions marked in pink except for E114Q (FAEM- > FAQM) (b) Mcl-1a comparison of the sequence seen in the
crystal structures of Bim bound to the modiﬁed Mcl-1 in PDB entry 2NL9 with hMcl-1, mMcl-1, and hMcl-1#1. Sequence numbering is for human
Mcl-1. * signiﬁes sequence identity between hMcl-1 and mMcl-1. The sequence diﬀerences between 2NL9 and hMcl-1 are highlighted in pink and
the diﬀerences between hMcl-1 and hMcl-1#1 in blue. X is seleno-methionine. Full sequences (including tags) are in the Supporting Information.
Figure 3. Bcl-2#3 crystal structures: (a) Bcl-2#3 bound to Puma; (b) structure of Puma bound to Bcl-2#3 (blue) and hMcl-1 (orange), overlaid on
Puma; (c). Structure of Bcl-2#3 bound to Puma (blue) and 1 (yellow); (d) detail of binding of 1 (yellow); and (e) detail of binding of 2 (grey) to
Bcl-2#3.
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Puma (Puma peptide N-terminally labeled with a ﬂuorescein
analogue), using hBcl-2 or hMcl-1.
2.3.2. 1H and 15N HSQC NMR. This 2D NMR experiment
on an 15N isotopically labeled protein sample generates a peak
for each amide with a chemical shift highly sensitive to the
chemical environment near that particular amide group.
Typically, spectra are acquired for 30−50 μM protein with
increasing concentration of the ligand, limited only by the
solubility of the ligand. Clearly deﬁned peaks for most amides
indicate a homogenous and soluble protein sample with
binding of the ligand to a deﬁned site, giving a titration of
movement of peaks of amides in the binding site (e.g., Figure
S1) from which Kd can be estimated if saturation can be
achieved. The initial HSQC NMR experiments used hMcl-1
and subsequent experiments used the more soluble and stable
mMcl-1.
2.3.3. Isothermal Titration Calorimetry. Experiments were
conducted, where compounds have suﬃcient solubility, at 25
°C by titration of a stock sample of the 100 μM compound
onto a solution of 10 μM hMcl-1 in a GE ITC200 instrument.
The lower solubility of later compounds sometimes required
titration of the protein onto the compound.10
2.3.4. Surface Plasmon Resonance. A direct binding
method was used, in which the protein (his-tagged Bcl-2#2
or hMcl-1 with a double his-tag18) was immobilized on an
NTA chip on a Biacore T100 instrument. Serial dilutions of
the ligand were then made to ﬂow over the surface, with
regeneration of the surface between each sample. A
competition or “aﬃnity in solution” method was developed
later for optimized compounds for both Mcl-111 and Bcl-2,10 in
which variable concentrations of the ligand with a ﬁxed
concentration of protein are made to ﬂow over an SPR chip
with a potent ligand bound (either the peptide or optimized
compound). This format of SPR assay was not used for the
compounds referenced here.
2.4. Bcl-2 Structural InformationX-ray Crystallog-
raphy. Although there were crystal structures of various BH3-
only peptides binding to Mcl-1 and Bcl-xL when we began our
project, there were no published structures determined by
either NMR spectroscopy or X-ray crystallography of such
peptides binding to Bcl-2. We determined the crystal structure
of Bcl-2#3 bound to the BH3-only peptide, Puma, and
compared it with a structure we determined of Puma bound to
hMcl-1 (Figure 3). There is an overall similarity in the binding
mode of Puma, with some small variation in the relative
orientations of the various helices that form the peptide
binding cleft.
Data shown for all compounds in this paper are μM values
for eKi for FP assay for that target [with data in brackets for
measurements of Kd by HSQC NMR (N), SPR (S), or ITC (I)
where available], unless the assay curve is incomplete, when it
is expressed as percentage inhibition at the highest
concentration. NMnot measurable at the concentrations
used in the assay (for FP2.5 mM or solubility limit).
We could only crystallize Bcl-2#3 in the presence of a high
aﬃnity ligand. Therefore, we were not able to determine
structures with the early hit series from fragment screening.
The ﬁrst crystal structure we determined of a small molecule
binding to Bcl-2#3 was with compound 1, an analogue of ABT-
737 (Figure 3d). This binds with a very similar pose to that
seen for the then-published structure of ABT-737 in Bcl-xL
(pdb code: 2YXJ19).
2.5. Mcl-1 Structural InformationX-ray Crystallog-
raphy. Similar to our experience with Bcl-2#3, we could only
determine the structures of hMcl-1 in complex with peptides
or small molecules with potency better than 100 nM, and the
success rate for cocrystallization was low. In the latter stages of
our Mcl-1 project, more routine crystal structure determination
was achieved with a maltose binding protein (MBP)-Mcl-1
fusion (as described elsewhere11), but this was not available at
the time of the studies reported here.
Figure 4 shows the crystal structure of hMcl-1 bound to the
indole acid compound 3, a tool compound derived from a
patent but reinforced by an indole acid fragment hit (see later).
Two copies of the ligand occupy the binding cleft. The ligand
in S2 is binding into a deep pocket that is not present in the
Puma-bound structure (Figure 2e). The ligand centered on S4
is between two molecules in the crystal packing environment,
which we believe is an artifact of crystallization as ITC
experiments demonstrate binding with 1:1 stoichiometry, and
the poor enclosure of the ligand in S4 makes it unlikely to be a
relevant pocket. The binding aﬃnity of 3 for hMcl-1 is 100 nM
eKi in the FP assay, consistent with ITC and SPR data (see
Figure S3), with selectivity of about 300-fold over Bcl-2.
Figure 4. hMcl-1 crystal structures: (a,b) structure of compound 3 bound to two sites on hMcl-1 with (c). Detail of binding of 3 that binds in the
S2 pocket; (d) comparison of hMcl-1 structures with 3 (yellow) and Puma (blue) bound with (e). Detail of the hMcl-1 binding surface for Puma
overlaid in blue on the observed binding position of 3 in the S2 pocket. The convention for the assay data is summarized in the legend to Figure 3.
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These structures demonstrate that there is conformational
ﬂexibility in both the proteins (more in Bcl-2 than in Mcl-1),
where both side-chain and main-chain movements can adjust
the surface of the protein to accommodate changes in the
ligand. These movements can substantially change the nature
of the binding surface, revealing additional pockets that
increase the “druggability20” of the protein.
2.6. Identifying and Characterizing Fragment Hits
Bcl-2. The initial NMR experiments on Bcl-2 were acquired
with the Bcl-2#2 protein at 10 μM. A total of 1088 fragments
were screened as mixtures of 8 (with each compound at 500
μM). The initial analysis suggested 82 hits, with a hit deﬁned
as showing competition with the 30 μM Puma peptide in three
ligand-observed NMR experiments [saturation transfer diﬀer-
ence spectroscopy (STD), water-LOGSY, and Carr−Purcell−
Meiboom−Gill]. However, there was some variability and
ambiguity in assigning hits because of protein instability giving
low signal to noise in the experiments. The initial set of hits
were remeasured in the ligand-observed experiments as
singletons and with a single-point and 1H, 15N titration
HSQC experiments, resulting in 24 validated hits which could
be grouped into 5 structural classes (Figure S4).
At this point in the project, the Bcl-2#3 protein had been
obtained for X-ray crystallography. This showed increased
stability and was adopted for all subsequent studies.
2.7. Identifying and Characterizing Fragment Hits
Mcl-1. The initial fragment hits came from two sources. First,
the 1064 fragments in the library at that time were screened at
500 μM each compound as mixtures of 8 against 10 μM hMcl-
1 using ligand-observed NMR with 25 μM Noxa-B peptide as
the competitor. A total of 39 fragments were conﬁrmed when
retested as singletons as competitive in all three NMR
experiments and fall into 13 diﬀerent classes (Figure S5).
Second, building on the observation that biaryl acids are often
found as binding to this type of protein−protein interaction
surface,21 commercially available analogues of two biaryl acids
(4 and 5) were assessed, and from this, the pyrazolo-acid 6 was
identiﬁed. Any compounds that were hits were also assessed by
1H, 15N HSQC NMR experiments and tested in the hMcl-1 FP
assay.
2.8. NMR-Guided Models. We were unable to determine
the structures for fragment hits binding to either Bcl-2 or Mcl-
1 by X-ray crystallography. Instead, we used an approach that
we refer to as NMR-guided models (NGMs). This technique is
suitable for proteins with a molecular weight up to around 35
kDa, with either a full assignment or partial assignment
(sometimes achieved with selective labeling of particular amino
acid types). The Experimental Section describes the methods
in detail, but in summary, the spectrum of the ligand is
assigned in the bound state using 13C, 15N purged 1D and
nuclear Overhauser spectroscopy (NOESY) experiments. A
full 3D 13C-edited, 13C, 15N-ﬁltered NOESY (so-called X-
ﬁltered NOESY) is then acquired, which identiﬁes intermo-
lecular NOEs between the ligand and protein. These restraints
are then used to ﬁlter ligand poses from docking into an
ensemble of protein conformations.
For each of Mcl-1 and Bcl-2, an ensemble of protein
conformations (including movement of side chains in the
putative ligand binding sites) was generated from the then
available structures (determined by X-ray crystallography or
NMR) supplemented by analysis of molecular dynamics (MD)
simulation and homology models. For Mcl-1, only peptide-
bound crystal structures were available, but a homology model
based on the available ligand-bound Bcl-2 structures and the
simulation suggested movement of helix 4. For Bcl-2, both
ligand and peptide-bound structures were available, and the
simulation suggested movement of helix 3. The compound of
interest was then docked into all enumerated protein
conformations and the three docking models that best satisﬁed
the observed NOEs were subjected to an induced-ﬁt docking
protocol. The docking models from ﬁxed-protein and induced-
ﬁt docking were examined side by side to select a ﬁnal model.
As crystal structures could be determined for larger
compounds such as 2 for Bcl-2 and 3 for Mcl-1, we generated
an NGM of 2 with Bcl-2 and 3 with Mcl-1 and compared these
to the X-ray structures (Figure S6). This conﬁrmed that the
Table 1. Optimisation of the Benzadioxane/Benzoxazole Series
Cmpd R1 R2 R3 R4 X A1 Mcl-1 eKi
2 (μM) Mcl-1 Kd
3 (μM) Bcl-2 eKi
4 (μM)
15 −NMe2 H H O NM 2600 NM
21 −OH H H O 40 280 300
225 −OH H CH2Ph O 40 85 (S-140) 80 (N-210)
23 −OH H H H N 500 360 NM
24 −OH Et H H N 20 220 500
25 −OH CH2Ph H H N 40 40 (S-450) 800 (N-210)
26 −OH CH2Ph H H N R 30 110 NM
27 −OH CH2Ph H H N S 40 140 NM
285 −OH CH2Ph Me H N R 47 70 93
aNMnot measurable at top concentration tested, usually 2.5 mM or solubility limit;1 a blank means the racemic compound was tested;2 eKi (μM)
is measured by Mcl-1 FP assay;3 Kd is measured by
1H, 15N HSQC (S is Kd measured by SPR);
4 eKi is measured by Bcl-2 FP assay (μM unless
incomplete assay curve, when expressed as percentage inhibition at the top concentration), N is Kd measured by
1H, 15N HSQC;5 and NGM is
generated.
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NGM can provide an adequate model for compound
optimization for both the proteins.
2.9. Hit IdentiﬁcationBcl-2. A number of fragment
series were explored for Bcl-2 and representatives of the hit
series emerging for Mcl-1 (see later). The aﬃnity for Bcl-2 of
various fragments and fragment-derived series was low (see
Table 1 and Figure 5) and there was no selectivity for Bcl-2
over Mcl-1, so the series were not progressed further for Bcl-2.
However, a number of thienopyrimidines (such as 7, 8, 9)
were identiﬁed in the near neighbor screening, which showed
emerging SAR and selectivity for Mcl-1 (see later).
It was striking that a number of benzodioxanes were
identiﬁed for both targets, such as 10. The Mcl-1 project also
identiﬁed benzodioxoles such as 11 (see later) and limited
SAR identiﬁed 12 with an aﬃnity of 67 μM for Bcl-2#3 by 1H,
15N HSQC and with suitable physicochemical properties such
that an NGM could be determined for binding to Bcl-2#3.
This collection of results suggested that such a semisaturated
fused-ring system could occupy the S2 pocket in Bcl-2. We also
determined the crystal structure of the then-leading candidate
for Bcl-2 (ABT-2635, 13) and realized, as shown in Figure 6,
that piperazine of 13 overlays with the bromobenzene in 12,
Figure 5. Compounds referenced in this paper (see also Table 1 and other ﬁgures). The convention for the assay data is summarized in the legend
to Figure 3.
Figure 6. Design of the hybrid Bcl-2 compound showing on the left the experimentally determined pose (Bcl-2 protein structure omitted) for each
of (a) crystal structure of ABT-263, 13; (b) NGM model of binding of benzodioxole, 12, and (c) crystal structure of the hybrid compound, 14. The
convention for the assay data is summarized in the legend to Figure 3.
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suggesting that chlorobenzene of 13 could be replaced by
benzodioxole of 12. This hybrid compound (14) was
synthesized and it binds with an aﬃnity of around 1 nM (FP
data conﬁrmed by SPR, data in Figure S1), although it has only
weak cellular activity (data not shown) and was not pursued
further. However, the crystal structure of 14 bound to Bcl-2#3
(Figure 6c) conﬁrms that the design strategy was correct and
provides further conﬁrmation that the NGM approach does
generate poses for small molecules that can be exploited in
synthesis.
After exploring the various fragments and hit series for
nearly a year, a publication from UCB22 revealed tetrahy-
droisoquinoline amide substituted phenyl pyrazoles as potent
and selective Bcl-2 inhibitors. A novel representative of the
series, 2, was synthesized, characterized, and the crystal
structure bound to Bcl-2#3 was determined (Figure 3c).
This provided the hit series, which was subsequently optimized
to a clinical candidate,10 through a structure-guided design that
will be described elsewhere.
2.10. Hit IdentiﬁcationMcl-1. It is challenging to
evolve fragments in the absence of detailed structural
information, so the initial exploration for Mcl-1 aimed to
generate SAR through assessment of near neighbors of the hits
identiﬁed from fragment screening that were available in the
Vernalis in-house library. This library is held on 96-well plates
and where more than 20 near neighbors were present, the
whole plate was screened. In total, over 2000 compounds were
screened and four hit series emerged: benzodioxanes such as
15; aminothiazoles as exempliﬁed by 16 (a serendipitous hit
from screening a plate of compounds), pyrazolo acids
exempliﬁed by 6 (a near neighbour of indole acid fragment
hits such as 17), and the thienopyrimidine series which were
fragment hits for both Mcl-1 and Bcl-2 (7−9, 18, 19).
Preliminary exploration of the SAR around these series was
informed by the structural models for binding derived from the
NGMs (see Figure 7).
2.10.1. Benzodioxane/Benzoxazines. Analogues of benzo-
dioxane fragment 15 were explored by purchase or synthesis,
leading to the optimized benoxazine 20 as summarized in
Table 1. Although 15 had very weak aﬃnity for Mcl-1, the
carboxylic acids, such as 21, were more potent, and an NGM
was generated for the analogue 22. The model (Figure 7a)
suggests dioxane is not making speciﬁc interactions, and a
nitrogen atom (i.e. benzoxazine) could oﬀer a vector into the
S2 pocket. Although oxazine 23 binds more weakly than its
equivalent dioxane, 21, introduction of an ethyl (24) and then
benzyl (25) gave increased potency with no preference for R
(26) compared to S (27) stereoisomer. Additional modiﬁca-
tions explored around the benzene moiety of the benzoxazine
and an NGM was generated for one of the most potent
compounds, the R enantiomer 28, demonstrating the success
of the NGM model in the guiding design. However, limited
progress was made in improving the ligand eﬃciency. Other
bicyclic compounds such as benzodioxole 11 were identiﬁed
under the NIH Pubchem initiative from a ﬂuorescence
resonance energy transfer-based uHTS conducted to identify
inhibitors of the Mcl-1/NOXA or Mcl-1/Bid interaction at the
Emory University Molecular Libraries Screening Centre
(bioassay 1021 and 1022 in https://pubchem.ncbi.nlm.nih.
gov/bioassay). 11 had some selectivity for Mcl-1 over Bcl-2
but poor behavior in biophysical assays. The benzoxazine and
benzodioxole series of compounds were not pursued further
for Mcl-1.
2.10.2. Aminothiazoles. There were aminothiazole-contain-
ing fragment hits (such as 15which was classiﬁed as a
benzodioxane series member), but the series actually
developed from analysis of near neighbors of other fragment
hits and from serendipitous hit identiﬁcation during whole-
plate screening in the near neighboring process. Compound 16
is a typical representative of the series which had reasonable
potency and generated an NGM. A number of analogues were
explored synthetically, but the series was not progressed
because of poor physicochemical properties (mainly solubil-
ity), with modiﬁcations to improve solubility, leading to a rapid
drop in ligand eﬃciency.
2.10.3. Pyrazoloacids. The commercially available pyrazo-
loacids were investigated and for one (29), an NGM was
obtained, which reinforced the emerging hypothesis that the
acidic moiety binds to R263, anchoring the compound with an
aromatic group pointing toward the S2 pocket. However, the
series was not progressed as most of the compounds had poor
solubility and so were diﬃcult to characterize.
2.10.4. Indole Acids. The fragment screen identiﬁed a
number of indole (and related fused ring) acids as hits for Mcl-
1. In addition, a patent from Abbott reported indole acids from
an HTS screen23 (subsequently optimized to potent Mcl-1
compounds24). A number of analogues were synthesized,
including 3, which had suﬃcient potency to give a crystal
structure (Figure 4) and showed some selectivity for Mcl-1
over Bcl-2. This provided a compound that could be used to
validate the structural biology and biophysical assays for the
project. However, as well as not being novel, the series showed
very high plasma protein binding and so was not pursued
further.
2.10.5. Thienopyrimidines. The initial screen of the
Vernalis compound collection for near neighbors of fragment
hits (as described above) was performed before the Bcl-2
project was underway and identiﬁed some thienopyrimidines
(such as 18 and 19) with activity in the FP assay. However,
Figure 7. hMcl-1 NGM structures: molecular surface of the Mcl-1
structure used to generate models of compound binding with (a)
selected amino acid side chains of BIM from the 2NL9 structure
shown in stick with grey carbon atoms with the NGM-derived pose of
the R-enantiomer of benzadioxane 22 (purple) (the model of the S-
enantiomer was identical except for slight rearrangement of the
benzodioxane moiety); NGM-derived pose of (b) benzoxazine 28 in
stick with green carbon atoms superposed on 22; (c) pyraloacid 29
with orange carbons; and of (d) aminothiazole 20 with yellow
carbons.
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this series was not pursued initially as other series looked more
promising. When the additional thienopyrimidines were
identiﬁed in the Bcl-2 project, it was found that this series
had tractable SAR, selectivity, and opportunities for
optimization against Mcl-1. The thienopyrimidines were
therefore adopted as the lead series, and the optimization
from the initial hit to a cell-active, high-aﬃnity, and selective
Mcl-1 inhibitor is described elsewhere.12
3. DISCUSSION
The discovery of the hit compounds that led to the Servier/
Vernalis clinical candidates for each of the Bcl-210 and Mcl-111
proteins provides an example of how structure-based drug
discovery can be enabled for the challenging task of inhibiting a
protein−protein interaction. The approach taken requires the
extension and integration of established techniques from across
many diﬀerent disciplines such as protein production, assay
development, biophysical measurement of protein−ligand
interactions, X-ray crystallography, and NMR spectroscopy.
The essential requirement for any structure-based drug
discovery approach is the production of protein material
suitable for a range of biophysical and functional assays. At the
time we initiated our Mcl-1 and Bcl-2 projects, there were
published constructs that had been successfully used for NMR-
based structural-based discovery for Bcl-26 and some
preliminary structural studies of Mcl-1.17 These published
constructs did not have the required stability or solubility in
our hands, and so, a number of modiﬁcations were made. For
Bcl-2, the main improvement came from structure-guided
modiﬁcation of the surface of the protein to alter physical
properties, using information from available crystal structures
of the more tractable homolog, Bcl-xL. The Mcl-1 project
required more substantial protein engineering. Although
variations in the puriﬁcation tag (and cleavage approach)
generated human Mcl-1 (hMcl-1) protein suitable for FP assay
and crystallography, the protein did not have the solubility and
stability required for the longer timescale of 1H, 15N NMR
experiments, and so, mouse Mcl-1 (mMcl-1) was used.
The biophysical and structural methods used in these early
hit identiﬁcation studies included a number of mutations in the
protein to improve properties such as solubility, stability, and
crystallzsation. Although SAR was mainly derived from the FP
assay against the wild-type protein, there is a danger that these
mutations might lead to anomalies in the biophysical or
structural data generated. For Bcl-2, the proﬁle of binding to
diﬀerent BH3-only peptides (Table S1) gave conﬁdence that
the Bcl-2#3 construct was appropriate for the biophysical
assays. The diﬀerence in sequence between mouse and human
Mcl-1 was not considered for the early hit compounds
reported here. This was an issue for compounds later in
optimization (9-fold higher aﬃnity for a published compound
in human vs mouse11), probably because of the L246F
mutation which aﬀects compounds binding deep into the S2
pocket. However, this interaction is not exploited in the early
hit compounds.
The use of several assay formats can aid establishing reliable
measurements of aﬃnity for the interaction of weakly binding
compounds to proteins such as Mcl-1 and Bcl-2 where there
are large hydrophobic clefts, which could promote poor
compound behavior. For example, we found considerable
variability in the measurement of aﬃnity using an early version
of the FP assay with values that were inconsistent with
measurements by other biophysical methods. Each of the assay
formats has diﬀerent dynamic ranges and diﬀerent require-
ments for the protein construct, for the behavior of the
compound and protein in solution (solubility, aggregation)
and the amount of the reagent required. Most of the cross-
validation of binding during hit identiﬁcation and hit
optimization used 1H, 15N HSQC measurements of aﬃnity
(to a Kd of around 10 μM) with either ITC or SPR used to
measure binding aﬃnity of more potent compounds to these
proteins.10,11 The 1H, 15N HSQC measurements are the most
robust as they directly measure the protein and ligand state.
Each experiment conﬁrms the solubility and concentration of
the protein and ligand, the folded state of the protein and the
integrity of the ligand. In addition, the measurements can give
an indication of which site the ligand is binding to. There are
varying issues with the other assay formats, including spectral
interference with the FP assay, solubility for ITC, and solubility
and nonspeciﬁc binding to the chip surface, giving non-
stoichiometric responses for SPR. Such anomalies can be
particularly acute for low-aﬃnity compounds. The consistency
of compound behavior in the assays was one of the
contributing factors to selecting thienopyrimidines as hits to
be progressed for Mcl-1.
A number of groups have reported25−28 on how the number
of hits from a fragment screen provides an indication of the
intrinsic ability of the protein to bind small molecules
(sometimes referred to as druggability; the phrase ligandability
is more appropriate29). The earliest example of this is from the
Abbott group.26 Our own analysis of fragment screening
campaigns some years ago25 highlighted that a low hit rate in
fragment screening gave an indication of how diﬃcult it would
be to identify lead-like compounds for a target. As discussed in
that paper,25 this could be due to the nature of the protein
interaction surface (such as the essentially ﬂat, hydrophobic
cleft of β-catenin, PPI-3 in that paper) or the intrinsic ﬂexibility
of the binding site, providing an entropic penalty for any ligand
binding such as for the ATPase site on Hsp70. The number of
validated fragment hits for Bcl-2 (24) and Mcl-1 (39) is higher
than the number which could be anticipated for a fairly large,
hydrophobic cleft. However, the NGMs (e.g., Figure 6)
suggest that many of the hits exploit the charged residue in the
center of the cleft (R146 for Bcl-2 and R263 for hMcl-1), as
conﬁrmed in subsequent crystal structures. The diﬀerence in
the hit rate from the fragment screen between the two targets
could be due to diﬀerent intrinsic ﬂexibilities and ligandability
of the proteins. There are indications from crystal structures
that Bcl-2 is more ﬂexible than Mcl-1. The root-mean-square
deviation (rmsd) for least squares overlap on main chain atoms
for the published crystal structure of Bcl-2 bound to BAX
(PDB code: 2XA0) compared to the structure bound to S
55746 (6GL810) is 3.6 Å; this contrasts with an rmsd of 1.7 Å
for Mcl-1 bound to Bim (2NL9) compared to the structure
bound to S 63845 (5LOF11). The challenge of identifying lead
candidates may also be reﬂected in the diﬀerent numbers of
reported clinical candidates (including our own series, 2 for
Bcl-24 and at least 5 for Mcl-17,9,30).
The crystal structure of Bcl-xL was determined some time
ago,15 and it was our experience (not reported here) that we
were able to determine many crystal structures of this BH3
family protein in complex with both pro-apoptotic peptides
and with various ligands. However, there remain relatively few
published crystal structures for Bcl-2. The early drug discovery
relied on NMR structure determination,16 and it was our
experience that crystal structures with small molecule ligands
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were only obtained once high aﬃnity binding had been
achieved (as shown in Figure 3, see also ref 10). For Mcl-1, it
was relatively straightforward to obtain crystal structures with
peptides bound (as shown in Figures 1 and 3), but again
crystallization of the native hMcl-1 complexed with small
molecules required high-aﬃnity ligands.11 For both proteins,
we were unable to obtain crystals of the apo protein, perhaps
because the ligand was required to stabilize a conformation of
the protein which crystallized. One recent innovation is to fuse
Mcl-1 with MBP.31 This stabilizes the protein and generates
crystals with the ligand binding pocket available for soaking of
ligands. Using a similar strategy, we were able to obtain many
crystal structures of MBP-Mcl-1 with both low- (Figure S6)
and high-aﬃnity11 compounds bound.
As discussed, the early structure-based design work at
Abbott on Bcl-2 relied on structures determined by NMR
spectroscopy. Such NMR structures require considerable eﬀort
in labeling with multiple isotopes (2H, 13C, 15N), the collection
of many 2D NMR spectra, and the time-consuming assignment
of each peak in the spectrum to individual nuclei. Once
assigned, NOE experiments can then identify speciﬁc protein−
protein and protein−ligand interactions from which a full
structure determination can be achieved. This takes some time
and in addition, optimization of the ligand can lead to changes
in the spectrum which require reassignment to be performed.
We adopted an NGM approach. This begins with generating
computational models that reﬂect the possible conformations
for the protein and a cascade of rigid followed by ﬂexible
docking protocols to generate putative binding poses for the
ligand in the protein binding site. The NMR experiments do
not require full assignment but generate suﬃcient information
to identify which nuclei in the ligand are interacting with which
nuclei on the protein. These distances are then used to select
the model for the ligand binding to the protein from the
docking poses.
The NGM approach was initially validated by the compound
design illustrated in Figure 6. The NGM of a fragment-derived
compound (11) was used to design a high-aﬃnity compound
(14) which merged the fragment with part of an established
Bcl-2 binding motif (13). The subsequent crystal structure
conﬁrmed that the NGM had successfully identiﬁed the correct
binding mode for 11. NGMs were generated for the various hit
series for Mcl-1 and can assist in optimization, as shown for the
benzodioxane to benzoxazine optimization in Figure 4b.
However, there are limits to the extent to which the NGM
binding modes can be used to rationalize observed aﬃnity and
selectivity. An NGM was generated for the thienopyrimidine
30 binding to Bcl-2. As can be seen in Figure S6, there is a
signiﬁcant diﬀerence in the binding pose of the central
thienopyrimidine motif seen in this NGM compared to that
seen in the later determination of the crystal structure of the
closely related compound, 9, determined in MBP-hMcl-1
(note that the pose of the thienopyrimidine core in 9 was
retained into the optimized compounds such as S 6384511). It
may be that compounds binding with around 200 μM (30) to
500 μM (9) aﬃnity do adopt diﬀerent conformations, for
example, to accommodate the additional aromatic ring in the
naphthalene of 30 and the NGM is reporting an incorrect
pose, or the change in orientation is due to diﬀerences between
Mcl-1 and Bcl-2 in this pocket. Because of this uncertainty, it
was diﬃcult to provide a structural rationale for the consistent
selectivity for Mcl-1 over Bcl-2 seen for the initial
thienopyrimidine series. However, the initial SAR for this
series (described elsewhere12) was suﬃcient to guide early
optimization without the support of structural information.
The fragment screening against each of the targets identiﬁed
several hit series. The consistent feature in most of the
fragment hits for both of the proteins is a negative charge
which binds the charged arginine side chain in Mcl-1 (R263)
or Bcl-2 (R146), which “anchors” the compound as seen in
Figures 4 and 7, and this is retained in the optimized
compounds such as 1 for Bcl-2 and S 6384511 for Mcl-1.
However, the fragment hit 11 demonstrates that small
uncharged compounds can bind to Mcl-1, as also seen for
the early hit 2 binding to Bcl-2 and retained in the optimized
compound S 55746.10 Although the initial fragment hits did
not lead directly to the lead compounds for either of these
targets, the experience with the fragments allowed the assays
and platform to be established and validated, such that good
quality hits could be recognized when they become available.
4. CONCLUSIONS
We have demonstrated how the combination of biophysical
and structural methods enabled structure-based discovery
platforms to be built for each of the Bcl-2 and Mcl-1 proteins.
Such target enablement is increasingly a barrier to establish
drug discovery for many of the recently proposed target classes
identiﬁed by modern “omics” technologies. Also, as well as the
increasing number of protein−protein interaction targets,2
similar challenges exist for large multidomain, multiprotein
complexes and intrinsically disordered proteins. Establishing
such a platform can take some time and resourcea tool
compound is usually needed to validate the assays, but the
assays are needed to identify the tool compound. However,
such investment is needed to identify compounds of suﬃcient
potency, selectivity, and cellular activity to demonstrate
whether inhibition (or activation) delivers the expected eﬀect
on the biology of the system. The thienopyrimidine series
provided compounds which characterize the eﬀect of Mcl-1
inhibition on cells.11,12
5. EXPERIMENTAL SECTION
5.1. Materials. Peptides were obtained from Biopeptide
LLC. The peptide F-Puma (31) was used for assays.
Puma has the sequence RGEEEQWAREIGAQLRR-
MADDLN
Puma-S has the sequence EEEQWAREIGAQLRRMADD
Peptide Bim has the sequence DMRPEIWIAQELRRIG-
DEFWAYYARR
Peptide Noxa-B has the sequence PADLKDECAQLR-
RIGDKVNL
5.2. Methods. 5.2.1. Protein ProductionBcl-2. Codon-
optimized genes encoding respective Bcl-2 proteins were
synthesized (DNA2.0, now ATUM) and ligated to pET28a
(Bcl-2#2) or pET21a (Bcl-2#3 and hBcl-2) between the NdeI
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and XhoI sites. The sequences of the proteins are given in the
Supporting Information.
5.2.2. Expression of Bcl-2 Proteins. Escherichia coli BL21
(DE3) pLysS cells were transformed with respective Bcl-2-
encoding plasmid and cultured at 37 °C in 10 ﬂasks each
containing 1 L Luria−Bertani (LB) supplemented with 50 μg/
mL of kanamycin (for Bcl-2#2) or 100 μg/mL of ampicillin
(for Bcl2#3 and hBcl-2). Once the culture had reached an
OD600 of 0.6, 1 M IPTG was added to each ﬂask to induce
expression (1 mM ﬁnal concentration). The cells were pelleted
after 16 h at 18 °C via centrifugation (10 000 rcf, 20 min) and
stored at −80 °C. For the production of labeled protein for
NMR studies, complex M9 media supplemented with 13C-
labeled D-glucose and/or 15N-labeled ammonium sulphate was
used instead of LB.
5.2.3. Puriﬁcation of Bcl-2 Proteins. Cell pellets were
resuspended in 200 mL of lysis buﬀer (50 mM Tris-HCl, 500
mM NaCl, 0.5 mM DTT, 10% (w/v) glycerol, and pH 8.0)
containing Roche Complete ethylenediaminetetraacetic acid
(EDTA)-free protease inhibitor cocktail and DNase I (Sigma).
The resuspended cells were lysed by mechanical homoge-
nization. The lysed cells were centrifuged (41 000 rcf, 60 min)
and the supernatant was applied to a 5 mL of HisTrap FF
column (GE Healthcare) using an AKTA FPLC system (GE
Healthcare). Column-bound protein was washed with lysis
buﬀer containing 25 mM imidazole and then eluted with lysis
buﬀer containing 500 mM imidazole. The eluted protein was
then applied to a HiLoad 26/60 Superdex 200pg column (GE
Healthcare) in sizing buﬀer (20 mM Tris-HCl, 200 mM NaCl,
2 mM EDTA, 1 mM DTT, and pH 8.0) and stored at −80 °C.
5.2.4. Protein ProductionMcl-1. Human Mcl-1 (hMcl-1)
and mouse Mcl-1 (mMcl-1) were generated by gene synthesis
(Celtek BioScience, TN, USA/ATUM, CA, USA). hMcl-1#1
was generated by a DNA shuﬄing technique of fragments from
hMcl-1 and mMcl-1. These genes were introduced into a
number of diﬀerent expression vectors as listed in the
Supporting Information.
5.2.5. Expression of Mcl-1 Proteins. The Mcl-1 constructs
were expressed in E. coli BL21 (DE3) pLysS. For material that
required isotopic labeling, EPBNF (EnPresso, Germany) or
M9 media was supplemented with 15N (NH4)2SO4 and/or
13C
D-glucose (CIL, MA, USA).
5.2.6. Puriﬁcation of the MBP-hMcl-1 Protein. The
expression and puriﬁcation of this protein are described
elsewhere11
5.2.7. Puriﬁcation of Other Mcl-1 Proteins. Puriﬁcation
involved either Ni2+ aﬃnity followed by ion-exchange/size-
exclusion chromatography or initial capture by GST aﬃnity
chromatography. Where needed, the resulting protein was
incubated with either PreScission protease (GE Healthcare,
USA) or thrombin to yield untagged proteins. Cleaved
material was further puriﬁed by either ion-exchange or size-
exclusion chromatography.
5.2.8. NMR Experiments to Characterize Binding. All
NMR spectra were acquired at 298 K on a Bruker AVANCE
600 MHz spectrometer with either a TCI or a QCI-F
cryogenically cooled probe, including a z-axis pulse-ﬁeld
gradient coil. Dissociation equilibrium constants (KD) of
compounds were determined by monitoring the chemical shift
perturbations from the acquisition of a series of 2D 1H, 15N
HSQC spectra with increasing compound concentration and
analyzed with MNOVA Binding (MNova, Mestrelab Research,
Santiago de Compostela, Spain) using a single binding site
model. Titrations were acquired on 50 μMmMcl-1 in MES pH
6.0 buﬀer or 20 mM Tris pH 7.8, 50 mM NaCl, 2 mM DTT,
and on 30−40 μM Bcl-2#3 in 50 mM Tris, pH 7.5.
5.2.9. Assignment/NOE Detection for NGMs. The back-
bone and side-chain resonances of apo Bcl-2#3 (concentration
and buﬀer) and apo mMcl-1 (concentration and buﬀer) were
achieved using three-dimensional HNCO, HNCA, HN(CA)-
CB, CBCA(CO)NH, and HBHA(CBCACO)NH and HCCH-
TOCSY experiments and analyzed using CCPN Analysis.32
For each NGM, the HSQC titration was followed to achieve
saturation of the protein with the ligand. For ligands in slow to
medium exchange, the collection of three-dimensional experi-
ments were performed to reassign the spectra. For ligands in
fast exchange, the resonance assignments were extrapolated
from those of the apo protein by comparing two-dimensional
1H, 13C HSQC spectra at increasing ligand concentrations.
Ligand−protein NOEs were detected from a 3D 1H, 13C-
edited, 13C/15N-ﬁltered NOESY acquired with a mixing time
of either 120 or 150 ms on 200 μM mMcl-1 in 50 mM MES/
bistris pH 6.0 or 200 μM Bcl-2#3 in 20 mM MES/bistris pH
7.4.
5.2.10. Calculation of NGMs for Mcl-1. Molecular
modeling was conducted either with the molecular operating
environment (MOE) (http://www.chemcomp.com) or Schro-
dinger (http://www.schrodinger.com) suites of software.
Analysis of the available BH3 public structures upon project
inception already suggested a signiﬁcant conformational
change between a peptide bound compared to a compound-
bound BH3 protein. However, there were only peptide-bound
Mcl-1 structures at the time this project was started. To
address the possibility of protein ﬂexibility, we ﬁrst carried out
an MD simulation of Mcl-1 (details below), and then, a protein
conformational ensemble was prepared for Mcl-1 for NGM
derivation. When enumerating such ensemble of conforma-
tions, we focused particularly on movements of helix 4
suggested by the internal MD simulation analysis of Mcl-1 and
also the side chain orientations of the residues involved in the
NOEs. In addition, to expand the diversity of protein
conformations, homology models based on ligand-bound Bcl-
2/Bcl-xL structures were built and added to the ensemble. The
compound of interest was then docked into all enumerated
protein conformations. The resulting docking models were
visually inspected, and the best three docking models in terms
of satisfying the observed NOEs were then subjected to the
induced-ﬁt docking protocol. A set of docking models from
ﬁxed-protein and induced-ﬁt docking was examined side by
side to nominate a ﬁnal model.
5.2.11. Mcl-1 MD Simulation. The published structure of
hMcl-1 bound to BIM (pdb code 2PQK13) was chosen to start
the MD simulation for Mcl-1. The missing loop connecting
helix 1 and helix 2 was rebuilt with MOE guided by the
structure of mMcl-1 bound to NOXA the peptide (pdb code
2JM633). The rebuilt Mcl-1 protein was prepared using
Schrodinger’s Protein Preparation Wizard,34 which added
hydrogens, assigned appropriate protonation and rotamer
states for residues, and performed restrained minimization.
The simulation system of apo hMcl-1 (starting from BIM
bound conformation) was built with the Schrodinger’s Maestro
interface in the NPT ensemble, with explicit TIP3P waters and
counter ions added to neutralize the overall charge of the
system. The default setup parameters were kept unless
mentioned speciﬁcally here. Periodic boundary conditions
were applied, and long-range electrostatic interactions were
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treated with Ewald sums.35 The MDs were performed with
Desmond36 at a constant temperature (300 K) and pressure
(1.01 bar), and coordinates were saved every 4.8 ps, keeping
the default settings. The AMBER ﬀ98SB force ﬁeld37 was used
for a 50 ns simulation. The simulation results were analyzed
with tools from Schrodinger and MOE. A set of diverse
conformations and 2PQK were included in the ﬁnal protein
conformational ensemble for NGM enumeration.
5.2.12. Mcl-1 Homology Models Based on Bcl-2/Bcl-xL.
The experimental ligand-bound Bcl-xL structures (pdb codes:
2O1Y, 2O2F, 2O21, 2W3L and 2YXJ) and ligand-bound Bcl-2
structure (compound 1) were used as templates. The sequence
alignments and model building were performed using MOE
with AMBER ﬀ99 force-ﬁeld37 and generalized Born
solvation.38 Up to 10 main-chain models were built for each
template.
5.2.13. Docking Details for Mcl-1. Prior to docking,
compounds were prepared with LigPrep from Schrodinger
and docking grids were generated by Glide39,40 on all protein
conformations. The default parameters were used. Compounds
were modeled in each of the protein conformations using the
Glide SP protocol from Schrodinger, generating up to 10 poses
while everything else was kept at default. The selected docking
models with reasonable NOE matching were subjected to
Schrodinger’s Induced-Fit docking protocol.41 All the resulting
docking models were visually inspected to propose a ﬁnal
model.
5.2.14. Computational Work for Bcl-2 NGMs. The
approach used to enumerate Bcl-2 NGMs is similar to that
described for Mcl-above. One diﬀerence was the availability of
ligand-bound Bcl-xL experimental structures at the time of the
project. Bcl-xL is highly analogous to Bcl-2 in sequences, and
the bound ligands also inhibit Bcl-2. This allows construction
of Bcl-2 ligand-bound homology models, which enhances the
diversity of the protein conformational ensemble but also
allows for anticipating Bcl-2 ﬂexibility in a more deﬁned
manner. The available experimental structures suggest that the
main ﬂexibility of Bcl-xL and likely for Bcl-2 comes from helix 3
upon ligand binding. Therefore, we explored helix 3 mobility
when generating a Bcl-2 conformational ensemble. The
compound of interest was subjected to the same docking
protocol as Mcl-1, ﬁxed-protein followed by induced-ﬁt
docking. Inspection of selected docking poses led to ﬁnal
models used for medicinal chemistry.
5.2.15. Bcl-2 Ligand Bound Homology Models. The
experimental ligand-bound Bcl-xL structures (PDB codes:
1YSG, 1YSI, 1YSN, 2O1Y, 2O2F, 2O2M, 2O2N, 2O21,
2O22, 2W3L, and 2YXJ) were extracted from PDB to use as
templates. The alignments and model building were performed
using MOE with AMBER ﬀ99 force-ﬁeld37 and generalized
Born solvation.38 Up to 10 main-chain models were built for
each template. A ligand-bound Bcl-2 X-ray structure
(compound 1) was later determined internally which validated
the homology model approach.
5.2.16. Docking Details for Bcl-2. Prior to docking,
compounds were prepared with LigPrep from Schrodinger
and docking grids were generated by Glide39,40 on selected Bcl-
2 protein conformations with default parameters. The Glide SP
protocol in the Schrodinger suite was employed to model
compounds in selected Bcl-2 protein conformations, generat-
ing up to 10 poses per compound per protein conformation.
The docking models with reasonable NOE matching were
subjected to Schrodinger’s Induced-Fit docking protocol.41 All
the resulting docking models were visually inspected to
propose a ﬁnal model.
5.3. Assays. 5.3.1. F-Puma Assay. The assays were carried
out in black-walled, ﬂat-bottomed, low binding, 384-well
plates. Compound [ﬁnal conc. 5% dimethyl sulfoxide
(DMSO)] was mixed in buﬀer (10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid, 150 mM NaCl, 0.05% Tween
20, and pH 7.4), containing 10 nM compound 31 (F-Puma)
and either 10 nM His-TEV-hMcl-1 or hBcl-2. Assay plates
were incubated ∼2 hours at room temperature and FP
measured on a Synergy 2 reader (Ex. 528 nm, Em. 640 nm, cut
oﬀ 510 nm). The binding of increasing doses of compound
was expressed as a percentage reduction in mP compared to
the window established between “DMSO-only” and “total
inhibition” controls (10−30 μM Puma). The inhibitory
concentrations that gave a 50% reduction in mP (IC50) were
determined, from an 11-point dose response curves, in XL-Fit
using a 4-Parameter Logistic Model (Sigmoidal Dose−
Response Model). Ki was subsequently calculated as previously
described.42 All FP data reported in this publication are the
average of at least three determinations. For most compounds,
the standard deviation in eKi values were within 15% of the
average; for some, the standard deviation was 40%.
5.3.2. Isothermal Titration Calorimetry. Double His-tag
TEV hMcl-1 was dialyzed prior to use in 2 L of 50 mM
Phosphate, 50 mM NaCl, 0.5% MTG (v/v) 1 mM EDTA at
pH 7.4 for 3 h at room temperature. The protein was dialyzed
using a 3.5 K molecular weight cut-oﬀ Slide-A-Lyzer cassette.
The protein solution was recovered, spin-ﬁltered through a
0.22 μM frit, and the resulting protein quantiﬁed by UV
absorbance at 280 nm using an extinction coeﬃcient of 20 970
M−1 cm−1. 500 mL of dialysis buﬀer was retained (remainder
used to rinse out SCHOT bottle) and degassed for a minimum
of 30 min under vacuum with constant stirring. Experiments
were performed on a GE ITC200 instrument. 100 μM
compound was titrated from the syringe into the cell
containing 10 μM protein. The solutions were carefully
matched to ensure same solvent and buﬀer conditions were
present in both the syringe and cell (this is to minimize heat of
dilution eﬀects). The ﬁnal solution was the dialysis buﬀer plus
1% DMSO. The experiment was performed over 25 injections
with stirring at 1000 rpm, gain setting high, and at 25 °C. Pure
water was used in the reference cell. The ﬁrst injection was 0.4
μL with a duration of 1 s with a gap of 150 s until the further
24 injections of 1.6 μL with a duration 6.1 and a 240 s interval
between injections. Data were analyzed using the vendor
supplied software, PEAQ-ITC Analysis Software. The data
model used was the single site model. The data shown are the
average of two independent experiments.
5.3.3. SPRDirect Binding. Experiments were carried out
on a Biacore T100 instrument (GE Healthcare) at 25 °C in
HBS-P buﬀer at pH 7.4 supplemented with 1 mM TCEP and
1% DMSO. Single his-tagged Bcl-2#2 or double His-TEV-
hMcl-1 proteins were immobilized on Series S NTA chips. The
surface in the experimental channel was consecutively treated
with 500 μM NiCl2 and 50 nM protein. Reference surfaces
without immobilized Ni2+ served as controls for nonspeciﬁc
binding and refractive index changes. The protein surface was
regenerated between experiments with 0.35 M EDTA and 40%
DMSO (both for 1 min, 15 μL min−1). Serial dilutions of the
compound in the running buﬀer were injected over the surface.
All sample measurements were performed at a ﬂow rate of 30
μL min−1. Data processing was performed using BIAevaluation
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1 (BIAcore GE Healthcare Bio-SciencesCorp) software.
Sensorgrams were double-referenced prior to global ﬁtting of
the concentration series to a 1:1 binding model.
5.4. Fragment Screening. The Vernalis fragment library
of approximately 1000 compounds43 was screened in mixtures
of eight compounds per sample on a Bruker DRX600 equipped
with a BACS-120 sample changer. Mcl-1 samples contained 10
μM hMcl-1 protein and 500 μM of each compound, in 20 mM
tris pH 7.4 50 mM NaCl, 100 μM DTT, and 10% D2O. Bcl-2
samples contained 12 μM Bcl-2#2 and 500 μM of each
compound in 50 mM tris pH 7.5, 50 mM NaCl, 250 μM DTT,
500 μM EDTA, and 10% D2O.
1H 1D, STD,44 the water ligand
observed via gradient spectroscopy (waterLOGSY),45 and
relaxation-ﬁltered spectra46 were acquired on all samples under
ICONNMR automation, using excitation sculpting to suppress
the solvent peak. Excitation sculpting used 2 ms square pulses
with γB1/2Π ≈ 250 Hz. A spectral width of 12 376 Hz was
used in all experiments, and all experiments were acquired at
298 K. Competition was determined by addition of the 25 μM
NoxaB peptide (Mcl-1) or 500 μM Puma peptide (Bcl-2),
following acquisition of the set of NMR experiments for each
sample, in order to conﬁrm speciﬁc binding at or near to the
active site. Data were analyzed as described previously47the
spectra were analyzed manually and competitive hits conﬁrmed
as singletons.
5.5. X-ray Crystal Structure Determination. 5.5.1. Crys-
tallisation of Bcl-2. The hBcl-2#3 protein was used for the
crystal structure of Bcl-2 complexed with compounds 1, 13,
and 14, and hBcl-2#3 was used for compound 2. In all cases,
the protein was initially complexed with the ligand by mixing
protein (4 mg/mL, 0.2 mM in 20 mM Tris buﬀer pH 8.0, 0.2
M NaCl, and 1 mM DTT) with 10-fold excess of compound
from 200 mM stock DMSO solution and incubated at 4 °C for
1 h and then concentrated to about 9 mg/mL (0.4 mM) before
being used for crystallization with commercial screens. For Bcl-
2 in complex with compound 1, crystals appeared after four
weeks in a droplet containing 1.4 M sodium/potassium
phosphate, pH 5.6. The bipyramidal crystal (with edge of
∼0.2 mm) was immersed in cryo-protection solution (1 M
Na/K phosphate pH 5.6, 30% glycerol) and ﬂash-frozen in
liquid nitrogen. For Bcl-2 in complex with Puma-S, crystals
appeared overnight and grew up to ∼0.2 mm in the longest
dimension over the following three days. Crystals grown from
0.2 M MgCl2, 25% PegMME 2k, 0.1 M Na acetate buﬀer pH
5.5 were prepared for data collection by cryo-protection
(immersion in mother liquor enriched in Peg1k by 10%) and
ﬂash-frozen in liquid nitrogen. For Bcl-2 in complex with
compound 2, crystals were obtained from 0.2 M Ca acetate,
15% Peg4k, and 0.1 M Tris pH 7.5. Crystals were harvested,
cryoprotected (immersion in mother liquor enriched in Peg1k
by 20%), and ﬂash-frozen in liquid nitrogen. For Bcl-2 in
complex with 13, crystals appeared overnight in a droplet
containing 0.2 M NaCl, 25% Peg3350, and 0.1 M Bis-Tris
buﬀer pH 5.5. Bipyramidal crystal was immersed in cryo-
protection solution (70% crystallisation buﬀer, 30% glycerol)
and ﬂash-frozen in liquid nitrogen. For Bcl-2 in complex with
14, crystals were grown from solution containing 0.15 M
KSCN, 20% Peg1500, and 0.1 M Na acetate buﬀer pH 5.5.
5.5.2. Crystallisation of Mcl-1. The hMcl-1 protein was
used for determination of the structure with BIM. Mcl-1
solution at ∼10 mg/mL was mixed with 10-fold excess of the
BIM peptide (water solution) and incubated overnight at 277
K. The formed complex was used for crystallization as
described in 2NL9.17 (0.2 M Zn acetate, 0.2 M Imidazole
pH 5.75, room temperature). hMcl-1#1 was used for the
structure with Puma. Mcl-1 solution at ∼10 mg/mL was mixed
with 10-fold excess of the Puma peptide (water solution) and
incubated overnight at 277 K. The formed complex was mixed
with equal volume of the crystallization reservoir (0.1 M
imidazole pH 7.0, 0.1 M Zn acetate, 25% Peg3350, 5%
ethylene glycol) in a hanging drop, vapor diﬀusion technique.
Elongated needles appeared overnight and were harvested in
2−4 days. MBP-hMcl-1 was used for the determination of the
structure of 9 bound to Mcl-1. Structure determination was
performed as described elsewhere11 for S64385 bound to
MBP-hMcl-1 PDB code 5LOF). His-thrombin-hMcl-1 was
used for structure determination with 3. Crystals were grown
in solution containing equal parts of protein solution (∼5−10
mg/mL) mixed an appropriate compound (with 3−5 fold
excess) and crystallization reservoir solution (1.8 M
ammonium citrate pH 7.0) in the hanging drop format of
the vapor diﬀusion technique, using 24-well Linbro plates.
5.5.3. X-ray Data Collection. Suitable crystals for data
collection were ﬂash-frozen in liquid nitrogen after cryopro-
tection using the crystallization reservoir enriched in ethylene
glycol (Mcl-1) and Peg1k or glycerol (Bcl-2). Table S2
summarizes the data collection statistics, with data obtained
from ESRF and dynamic light scattering synchrotrons or single
crystal X-ray diﬀraction equipment consisting of rotating anode
generator RUH300 coupled with a Raxis-IV++ image plate
detector (Rigaku MSC instrument installed at Vernalis,
Cambridge, UK). Data were processed and scaled with
DENZO/Scalepack package48 for all structures except Bcl-2
with 30 which used d*TREK.49
5.5.4. X-ray Structure Determination. All software was
from the CCP4 package50 unless explicitly mentioned. The
structure of Mcl-1 complexed with the BIM peptide was solved
by molecular replacement using MolRep51 using the published
structure of Mcl-1 complexed with the BIM peptide (PDB
code: 2NL917) as a model. Subsequent Mcl-1 complexes were
solved using the Mcl-1 model stripped of the peptide. The
structure of the Bcl-2 complex with compound 1 was solved by
molecular replacement using MolRep using the published
crystal structure of Bcl-xL complexed with ABT-737 (PDB
code 2YXJ19) stripped of the compound and solvent. From
initial electron density maps, it became apparent that 1 is
present in the binding site of Bcl-2. Initial maps allowed
extension of the reﬁnement resolution range and correct
placement of side chains. At this point, diﬀerences between the
Bcl-2 and Bcl-xL sequence were clearly visible, and appropriate
changes were made in the model. In all cases, the reﬁned
structure of the relevant protein (stripped of the compound)
was used as a starting model for solving by molecular
replacement subsequent structures of the complexes of Mcl-1
or Bcl-2 with ligands. After structure solution, several cycles of
reﬁnement were conducted with Refmac552 software from the
ccp4 package, alternating with manual rebuilding using the
program COOT.53 Compounds were modeled in the surplus
peaks in diﬀerence Fourier electron density maps. Topology
ﬁles for the ligands were created by ProDrg54 (also from ccp4
package). Reﬁnement statistics for each new structure reported
in this paper are in Table S2.
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